Market Overview:
The global alpha-adrenoreceptor antagonists market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of hypertension and other cardiovascular diseases, rising geriatric population, and growing demand for novel therapies. However, the high cost of treatment is likely to restrain the growth of this market during the forecast period. Based on type, the global alpha-adrenoreceptor antagonists market has been segmented into oral and injection segments. The oral segment is expected to account for a larger share in terms of revenue in 2018 as compared to that generated by injection drugs owing to their easy availability and lower costs as compared to injectable drugs. However, with increasing preference for novel therapies over traditional ones among patients across all regions covered in this study, demand for injectable alpha-adrenoreceptor antagonists is anticipated grow at a higher CAGR than that witnessed by oral drugs during the forecast period (2018-2030).
Product Definition:
Alpha-Adrenoreceptor Antagonists are a type of drug that blocks the effects of adrenaline (a hormone) on the body's alpha receptors. Blocking these receptors prevents the constriction of blood vessels that can occur with high levels of adrenaline. This can help to improve blood flow and lower blood pressure in people with conditions such as hypertension.
Oral:
Oral is a route of administration which involves the use of drugs in the form of tablets, capsules or liquids without being injected. The oral drug absorption process is usually done through the gastrointestinal tract and depends on factors such as drug stability and pH level.
The growth factor in Alpha-Adrenoreceptor Antagonists market includes various factors that are driving and inhibiting oral drug demand globally.
Injection:
Injection is a process through which the active ingredient of pharmaceutical drugs is administered into the bloodstream via syringe or intravenous injection. The drug undergoes gradual release in to the bloodstream over a period of time.
Alpha-Adrenoreceptor Antagonist (ADA) market is one of the largest markets for Injection and it's usage accounts for more than 50% share by revenue globally.
Application Insights:
The hospital application segment dominated the global alpha-adrenoreceptor antagonists market in 2017, accounting for over 60% of the overall revenue. The growth can be attributed to an increase in cardiovascular diseases and rising geriatric population across the globe. According to a study published by WHO, it was estimated that cardiovascular diseases are one of the leading causes of death globally and this number is expected to rise drastically by 2030.
Clinic applications include self-medication and healthcare professionals use these drugs as second line treatment for patients with mild hypertension or on other occasions when blood pressure remains uncontrolled despite medication adjustment or lifestyle modification. Increasing awareness about self-medication among patients with hypertension is also likely to contribute significantly towards segment growth during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The growth of this region can be attributed to the presence of key players such as Pfizer Inc.; Ortho-McNeil Pharmaceutical, Inc.; and Janssen Pharmaceutica, LLC. Moreover, these companies are constantly engaged in formulating new products to meet unmet needs of patients and increasing their customer base. For instance, in May 2018, Ortho-McNeil announced completion of phase 3 clinical trial for evaluationof ANAptiva XT which is an oral alpha2 adrenergic antagonist tablet for once daily dosing. This product is indicated for treatment of hypertension and urinary retention due to bladder spasms associated with SUI or urge incontinence caused by overactive bladder (OAB).
Growth Factors:
- Increasing prevalence of hypertension and other cardiovascular diseases: The global prevalence of hypertension is estimated to be around 1.13 billion in 2015 and is projected to reach 1.56 billion by 2025. This will create a large pool of patients who will require treatment, thereby driving the demand for alpha-adrenoreceptor antagonists drugs.
- Growing geriatric population: The global geriatric population is expected to grow at a CAGR of 5% from 2016 to 2020, reaching nearly 2 billion by 2030. This growing population is susceptible to various age-related diseases such as hypertension, which will drive the demand for alpha-adrenoreceptor antagonists drugs in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Alpha-Adrenoreceptor Antagonists Market Research Report
By Type
Oral, Injection
By Application
Hospital, Clinic
By Companies
Sanofi, Pfizer, Pro Doc, Concordia Pharmaceuticals, Covis Pharmaceuticals, Aspri Pharma, Roerig, Greenstone, Boehringer Ingelheim, Cardinal Health, Sanofi, Glaxosmithkline, Actavis, Merck, Jubilant Generics, Astellas Pharma, Allergan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
191
Number of Tables & Figures
134
Customization Available
Yes, the report can be customized as per your need.
Global Alpha-Adrenoreceptor Antagonists Market Report Segments:
The global Alpha-Adrenoreceptor Antagonists market is segmented on the basis of:
Types
Oral, Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Pfizer
- Pro Doc
- Concordia Pharmaceuticals
- Covis Pharmaceuticals
- Aspri Pharma
- Roerig
- Greenstone
- Boehringer Ingelheim
- Cardinal Health
- Sanofi
- Glaxosmithkline
- Actavis
- Merck
- Jubilant Generics
- Astellas Pharma
- Allergan
Highlights of The Alpha-Adrenoreceptor Antagonists Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injection
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Alpha-Adrenoreceptor Antagonists Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Alpha-adrenoreceptor antagonists are medications that block the action of alpha-adrenergic receptors. Alpha-adrenergic receptors are located in the brain and spinal cord, and they play a role in controlling blood pressure, heart rate, and other functions.
Some of the major players in the alpha-adrenoreceptor antagonists market are Sanofi, Pfizer, Pro Doc, Concordia Pharmaceuticals, Covis Pharmaceuticals, Aspri Pharma, Roerig, Greenstone, Boehringer Ingelheim, Cardinal Health, Sanofi, Glaxosmithkline, Actavis, Merck, Jubilant Generics, Astellas Pharma, Allergan.
The alpha-adrenoreceptor antagonists market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Alpha-Adrenoreceptor Antagonists Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Alpha-Adrenoreceptor Antagonists Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Alpha-Adrenoreceptor Antagonists Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Alpha-Adrenoreceptor Antagonists Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Alpha-Adrenoreceptor Antagonists Market Size & Forecast, 2018-2028
4.5.1 Alpha-Adrenoreceptor Antagonists Market Size and Y-o-Y Growth
4.5.2 Alpha-Adrenoreceptor Antagonists Market Absolute $ Opportunity
Chapter 5 Global Alpha-Adrenoreceptor Antagonists Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Alpha-Adrenoreceptor Antagonists Market Size Forecast by Type
5.2.1 Oral
5.2.2 Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Alpha-Adrenoreceptor Antagonists Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Alpha-Adrenoreceptor Antagonists Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Alpha-Adrenoreceptor Antagonists Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Alpha-Adrenoreceptor Antagonists Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Alpha-Adrenoreceptor Antagonists Analysis and Forecast
9.1 Introduction
9.2 North America Alpha-Adrenoreceptor Antagonists Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Alpha-Adrenoreceptor Antagonists Market Size Forecast by Type
9.6.1 Oral
9.6.2 Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Alpha-Adrenoreceptor Antagonists Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Alpha-Adrenoreceptor Antagonists Analysis and Forecast
10.1 Introduction
10.2 Europe Alpha-Adrenoreceptor Antagonists Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Alpha-Adrenoreceptor Antagonists Market Size Forecast by Type
10.6.1 Oral
10.6.2 Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Alpha-Adrenoreceptor Antagonists Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Alpha-Adrenoreceptor Antagonists Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Alpha-Adrenoreceptor Antagonists Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Alpha-Adrenoreceptor Antagonists Market Size Forecast by Type
11.6.1 Oral
11.6.2 Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Alpha-Adrenoreceptor Antagonists Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Alpha-Adrenoreceptor Antagonists Analysis and Forecast
12.1 Introduction
12.2 Latin America Alpha-Adrenoreceptor Antagonists Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Alpha-Adrenoreceptor Antagonists Market Size Forecast by Type
12.6.1 Oral
12.6.2 Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Alpha-Adrenoreceptor Antagonists Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Alpha-Adrenoreceptor Antagonists Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Alpha-Adrenoreceptor Antagonists Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Alpha-Adrenoreceptor Antagonists Market Size Forecast by Type
13.6.1 Oral
13.6.2 Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Alpha-Adrenoreceptor Antagonists Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Alpha-Adrenoreceptor Antagonists Market: Competitive Dashboard
14.2 Global Alpha-Adrenoreceptor Antagonists Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Pfizer
14.3.3 Pro Doc
14.3.4 Concordia Pharmaceuticals
14.3.5 Covis Pharmaceuticals
14.3.6 Aspri Pharma
14.3.7 Roerig
14.3.8 Greenstone
14.3.9 Boehringer Ingelheim
14.3.10 Cardinal Health
14.3.11 Sanofi
14.3.12 Glaxosmithkline
14.3.13 Actavis
14.3.14 Merck
14.3.15 Jubilant Generics
14.3.16 Astellas Pharma
14.3.17 Allergan
